{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:09:48Z","timestamp":1787317788687,"version":"build-2736575974"},"reference-count":34,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Despite the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), many patients with type 2 diabetes (T2D) require additional therapy to achieve glycated hemoglobin (HbA1c) targets. Few studies have explored real-world outcomes following GLP-1 RA failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This analysis evaluates different intensification approaches, timing, and outcomes in patients with T2D on GLP-1 RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was based on the AMD Annals database. From 191 041 patients on GLP-1 RAs between 2010 and 2022, individuals receiving a first therapeutic intensification were selected. Patients were stratified by intensification strategy; baseline characteristics were compared alongside HbA1c and weight changes at 6 and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 37 198 intensified patients, the majority received oral antihyperglycemic drugs (OADs), particularly those with higher body mass index, lower HbA1c, and shorter disease duration. Basal insulin (BI) was mainly added in those with higher HbA1c (8.9%) and longer diabetes. Intensification with BI or switch to fixed ratio combinations (FRCs) yielded the greatest HbA1c reduction (\u22120.92 and \u22120.85%; P &amp;lt; .001) and weight neutrality, whereas OADs led to a higher target achievement rate (36% with HbA1c &amp;lt; 7%) and persistent weight loss. Switching to BB was reserved for more complicated patients and it was associated with weight gain (+2.9\u2005kg; P &amp;lt; .001) and lower target achievement rate (16.8% HbA1c &amp;lt; 7%). Suboptimal insulin titration was observed across all strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding OADs or BI\/FRCs to GLP-1 RAs are optimal intensification strategies to provide glycemic control while avoiding weight gain. Target achievement rates are poor in individuals switched to insulin therapy. Therapeutic inertia remains a critical issue in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf229","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T09:35:55Z","timestamp":1744104955000},"page":"e4101-e4110","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Intensification Strategies and Metabolic Outcomes in Individuals With Type 2 Diabetes on GLP-1 RA Therapy"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3182-0453","authenticated-orcid":false,"given":"Pierpaolo","family":"Falcetta","sequence":"first","affiliation":[{"name":"Diabetes Unit, Azienda USL Toscana Centro , 50053 Empoli ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Zilich","sequence":"additional","affiliation":[{"name":"Mix-X Partner , 20122 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Baccetti","sequence":"additional","affiliation":[{"name":"Diabetes Unit, ASL Toscana Nord-Ovest , 54100 Massa-Carrara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Baronti","sequence":"additional","affiliation":[{"name":"Diabetes Unit, ASL Toscana Sud-Est , 58100 Grosseto ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-633X","authenticated-orcid":false,"given":"Davide","family":"Masi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome , 00161 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelio","family":"Morviducci","sequence":"additional","affiliation":[{"name":"Diabetology and Nutrition Unit, Department of Medical Specialities, ASL 1, S. Spirito Hospital , 00193 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Musacchio","sequence":"additional","affiliation":[{"name":"Associazione Medici Diabetologi , 20156 Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Muselli","sequence":"additional","affiliation":[{"name":"Rulex Innovation Labs, Rulex Inc , 16122 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ozzello","sequence":"additional","affiliation":[{"name":"AI-AMD National Group , 10190 Bruino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-2146","authenticated-orcid":false,"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[{"name":"I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio , 20149 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20122 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Salomone","sequence":"additional","affiliation":[{"name":"Diabetology and Nutrition Unit, Department of Medical Specialities, ASL 1, S. Spirito Hospital , 00193 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Verda","sequence":"additional","affiliation":[{"name":"Rulex Innovation Labs, Rulex Inc , 16122 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vezenkova","sequence":"additional","affiliation":[{"name":"Deimos Engineering srl , 33100 Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[{"name":"Department of Medical Surgical and Health Sciences, University of Trieste , 34149 Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ponzani","sequence":"additional","affiliation":[{"name":"Metabolism and Diabetes Unit , 16043 Chiavari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025111718533047600_dgaf229-B1","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"2025111718533047600_dgaf229-B2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"2025111718533047600_dgaf229-B3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"2025111718533047600_dgaf229-B4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","article-title":"Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis","volume":"137","author":"Khunti","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2025111718533047600_dgaf229-B5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2213-8587(16)30010-9","article-title":"The changing face of diabetes complications","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2025111718533047600_dgaf229-B6","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2025111718533047600_dgaf229-B7","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"2025111718533047600_dgaf229-B8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12916-023-03228-4","article-title":"Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"BMC Med"},{"issue":"1","key":"2025111718533047600_dgaf229-B9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025111718533047600_dgaf229-B10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/dom.12402","article-title":"Is insulin the most effective injectable antihyperglycaemic therapy?","volume":"17","author":"Buse","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2025111718533047600_dgaf229-B11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00592-022-01974-0","article-title":"De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes","volume":"60","author":"Falcetta","year":"2023","journal-title":"Acta Diabetol"},{"issue":"6","key":"2025111718533047600_dgaf229-B12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial","volume":"44","author":"Giugliano","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"2025111718533047600_dgaf229-B13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/phar.2648","article-title":"Clinical impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin","volume":"42","author":"Hopton","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2025111718533047600_dgaf229-B14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s13300-018-0429-x","article-title":"Treatment intensification in type 2 diabetes: a real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin","volume":"9","author":"Blonde","year":"2018","journal-title":"Diabetes Ther"},{"key":"2025111718533047600_dgaf229-B15","doi-asserted-by":"crossref","first-page":"870722","DOI":"10.3389\/fendo.2022.870722","article-title":"Free versus fixed-ratio combination of basal insulin and GLP-1 receptor agonists in type 2 diabetes uncontrolled with GLP-1 receptor agonists: a systematic review and indirect treatment comparison","volume":"13","author":"Jung","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025111718533047600_dgaf229-B16","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.numecd.2023.07.025","article-title":"RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) study group. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: the RESTORE-G real-world study","volume":"33","author":"Candido","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025111718533047600_dgaf229-B17","unstructured":"Falcetta P . 2025. Falcetta_supplemental_material. 10.6084\/m9.figshare.28532408."},{"key":"2025111718533047600_dgaf229-B18","doi-asserted-by":"crossref","first-page":"110669","DOI":"10.1016\/j.diabres.2023.110669","article-title":"Perspectives in weight control in diabetes\u2014SGLT2 inhibitors and GLP-1-glucagon dual agonism","volume":"199","author":"Iqbal","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2025111718533047600_dgaf229-B19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","article-title":"Body weight considerations in the management of type 2 diabetes","volume":"36","author":"Apovian","year":"2019","journal-title":"Adv Ther"},{"key":"2025111718533047600_dgaf229-B20","doi-asserted-by":"crossref","first-page":"111781","DOI":"10.1016\/j.diabres.2024.111781","article-title":"Profiles of sulfonylurea use in diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years","volume":"214","author":"Baccetti","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2025111718533047600_dgaf229-B21","author":"La Terapia del Diabete Mellito Tipo 2"},{"key":"2025111718533047600_dgaf229-B22","author":"Associazione Medici Diabetologi"},{"issue":"2","key":"2025111718533047600_dgaf229-B23","first-page":"50","article-title":"Hypoglycaemia remains the key obstacle to optimal glycaemic control\u2014continuous glucose monitoring is the solution","volume":"14","author":"Adolfsson","year":"2018","journal-title":"Eur Endocrinol"},{"issue":"2","key":"2025111718533047600_dgaf229-B24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"2025111718533047600_dgaf229-B25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s13300-024-01569-8","article-title":"The current and future role of insulin therapy in the management of type 2 diabetes: a narrative review","volume":"15","author":"McGill","year":"2024","journal-title":"Diabetes Ther"},{"issue":"9961","key":"2025111718533047600_dgaf229-B26","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"key":"2025111718533047600_dgaf229-B27","author":"Gazzetta Ufficiale"},{"issue":"4","key":"2025111718533047600_dgaf229-B28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2025111718533047600_dgaf229-B29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/dom.13946","article-title":"The importance of the initial period of basal insulin titration in people with diabetes","volume":"22","author":"Khunti","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2025111718533047600_dgaf229-B30","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1111\/dom.13840","article-title":"Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study","volume":"21","author":"Morieri","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2025111718533047600_dgaf229-B31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc06-1357","article-title":"Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups","volume":"30","author":"Yki-J\u00e4rvinen","year":"2007","journal-title":"Diabetes Care"},{"issue":"3","key":"2025111718533047600_dgaf229-B32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"issue":"11","key":"2025111718533047600_dgaf229-B33","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"Insulin glargine 4002 study investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"issue":"8","key":"2025111718533047600_dgaf229-B34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.clinthera.2023.06.006","article-title":"Achieving good metabolic control without weight gain with the systematic use of GLP-1-RAs and SGLT-2 inhibitors in type 2 diabetes: a machine-learning projection using data from clinical practice","volume":"45","author":"Giorda","year":"2023","journal-title":"Clin Ther"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf229\/62890725\/dgaf229.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4101\/62890725\/dgaf229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4101\/62890725\/dgaf229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:53:53Z","timestamp":1763423633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/12\/e4101\/8108462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf229","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,4,9]]}}}